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A B S T R A C T
Objective: The aim of this study was to assess the efficacy of lytic bacteriophages on Staphylococcus aureus
causing bovine mastitis, by in vitro and in vivo assays using Galleria mellonella and murine mastitis
models.
Methods: Between May and December 2016, ten S. aureus (five methicillin-resistant and five methicillin-
sensitive) isolates were isolated from milk samples of cattle with mastitis in Belgium and Norway. The
isolates were assessed in vitro for their susceptibility to four lytic bacteriophages (Romulus, Remus, ISP
and DSM105264) and subsequently in vivo in G. mellonella larvae and in murine mastitis model.
Results: Romulus, Remus and ISP showed a lytic activity against the S. aureus isolates in vitro. A larvae
survival rate below 50% was observed at 4 days post-inoculation (DPI) in the groups infected with a
methicillin-sensitive S. aureus isolate and treated with these three phages in vivo. An incomplete
recovery of the mouse mastitis was observed at 48 h post-inoculation (HPI) in the groups infected and
treated with the ISP phage in vivo.
Conclusions: The observations are much more pronounced statistically between the infected- phosphate
buffered saline (PBS)-treated and infected-phage-treated groups in G. mellonella and the murine mastitis
model demonstrating an effect of the phages against S. aureus associated with bovine mastitis.
© 2020 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial
Chemotherapy. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).
Contents lists available at ScienceDirect
Journal of Global Antimicrobial Resistance
journal home page : www.e l sev ier .com/ loca te / jgar1. Introduction
Staphylococcus aureus is responsible for several infections in
humans and animals and represents an important hazard in
public health. In humans, it is responsible for a range of illnesses
from mild skin disorders to invasive infections and life-
threatening in hospital settings [1]. It can also be community-
acquired, causing skin and soft tissue infections with moderate to1 Current address: Flanders Research Institute for Agriculture, Fisheries and Food
(ILVO), Technology and Food Science, Agricultural Engineering, Burg. Van
Gansberghelaan 115 Bus 1, 9820 Merelbeke, Belgium.
http://dx.doi.org/10.1016/j.jgar.2020.06.020
2213-7165/© 2020 The Author(s). Published by Elsevier Ltd on behalf of International Soc
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).severe symptoms in healthy and younger people [2]. In animals, S.
aureus infections impact livestock, companion animals and some
wild animals [3,4].
Besides their virulence properties, S. aureus can also acquire
genes conferring resistance to different antimicrobials. The most
widespread and frequent resistant strains are methicillin-resistant
S. aureus (MRSA) that are resistant to all β-lactams [5]. In the case of
bovine species, livestock-associated MRSA causes subclinical and
clinical mastitis which can lead to high financial costs [6,7]. To
avoid the continuous selection pressure for development and
dissemination of antimicrobial resistance by antimicrobial treat-
ment procedures, one strategy could be the use of bacteriophages
















































































































































































































































































































































































































































































































C. Ngassam-Tchamba et al. / Journal of Global Antimicrobial Resistance 22 (2020) 762–770 763Bacteriophages are viruses able to infect and replicate within
bacteria after injection of their genetic material [8]. They are
functionally classified into strictly lytic and temperate phages.
These strictly lytic phages are of interest for therapy [9]. To assess
the potential of phage therapy, studies generally rely on in vitro or
in vivo approaches using mammalian models. The lack of realistic
conditions of in vitro assay, the expensive costs and the ethical
requirements for in vivo models have led to the use of alternative
models such as G. mellonella larvae [10]. In this study, the efficacy of
lytic bacteriophages on S. aureus isolated from cows with mastitis
in Belgium and Norway was assessed in vitro and in vivo with G.
mellonella and murine mastitis models.
2. Methods
2.1. Bacterial and bacteriophage selection
Ten S. aureus isolates including five MRSA and five methicillin
sensitives (MSSA) were isolated in Belgium and Norway between
May and December 2016 from quarter milk samples of cows with
clinical or subclinical mastitis and stored at 80 C with 50% (v/v)
glycerol until further use (Table 1). Four well-defined lytic
bacteriophages were used: Romulus, Remus, ISP [11,12] and
DSM105264 (phage K) [13].
2.2. Phage preparation
The four phages were amplified using the S. aureus PS47 (NCTC
8325) strain for Romulus, Remus and ISP phages, and the S. aureus
DSM105272 (DSMZ) strain for the DSM105264 phage, as propaga-
tion strains. Phage lysates (100 mL) were added to 5 mL of the
propagation strain culture [optical density (OD600) = 0.2–0.3] in
Lennox broth (LB; Alfa Aesar, UK) [complemented with 1 mM of
calcium chloride (CaCl2) and magnesium sulfate (MgSO4)] and
incubated at 37 C, with shaking at 100 revolutions/min (rpm) until
the solution became transparent. Then, this solution was added
again to 500 mL of bacterial culture (with OD600 = 0.2–0.3) and
incubated overnight at 37 C with shaking at 100 rpm. After
addition of 1/20 of chloroform and incubation at 37 C for 10 min
with shaking at 100 rpm, the solutions were placed at 4 C until the
chloroform fraction separated. The solutions were then centri-
fuged at 4 C and 4600 rpm for 30 min and the supernatants were
filtered through a superposed filter of 0.45 mm and 0.22 mm. Phage
titration was performed in triplicate on a bacterial overlay of the
propagation strain (OD600 0.2–0.3) spread on an LB agar plate
(Applichem, Germany). To obtain high concentrated phage
solutions, a polyethylene glycol (PEG) precipitation was performed
[14]. After centrifugation (4600 rpm for 40 min at 4 C), the pellets
resulting from 50 mL of phage lysate were re-suspended in 1 mL of
phage buffer [10 mM Tris-hydrochloride (HCl), 10 mM MgSO4,
150 mM NaCl, pH7.5] and stored at 4 C until further use.
2.3. In vitro assays
2.3.1. Host spectrum and efficiency of plating
Ten mastitis-causing S. aureus isolates were screened for their
susceptibility to the four phages (Romulus, Remus, ISP and
DSM105264) on LB agar by the ‘spot-on method’ after serial
dilutions [15]. Lysis were recorded as no lysis (–), semi-confluent
lysis (SCL) or confluent lysis (CL). The efficiency of plating (EOP)
was then calculated (Table 2) [16].
2.3.2. Phage activity in LB
A total of 100 mL of the bacterial suspension at 106 colony-
forming units (CFUs)/mL and 100 mL of the phages (Romulus,
Remus, ISP, mix of the three latter phages or DSM105264) at 109
Table 2
Host spectrum test and EOP.
ID Origin Strain Romulus Remus ISP DSM_105264
Lysis EOP Lysis EOP Lysis EOP Lysis EOP
MRSA Flanders Ani_GT_111 – / – / – / – /
Wallonia Ani_LG_017 – / – / CL 6.80E-01 – /
Ani_LG_020 – / – / CL 9.10E-01 – /
Ani_LG_027 – / – / CL 1.10E+00 – /
Ani_LG_010 – / – / CL 6.80E-01 – /
MSSA Flanders Ani_Gt_110 – / SCL 5.30E-01 CL 1.30E+00 – /
Ani_Gt_117 – / SCL 1.10E-01 CL 3.30E-01 – /
Wallonia Ani_Lg_028 – / SCL 7.40E-01 CL 4.50E-01 – /
Norway Ani_Os_001 CL 3.57E+00 CL 1.90E-01 CL 1.30E+00 – /
Ani_OS_002 – / – / CL 9.10E-01 – /
CL, confluent lysis; EOP, efficiency of plating; ID, identification; MRSA, methicillin resistant S. aureus; MSSA, methicillin sensitive S. aureus; SCL, semi-confluent lysis.
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(complemented with 1 mM of CaCl2 and MgSO4) in triplicates. A
positive control containing 4 mL of LB broth with 100 mL of bacteria
and negative controls with 4 mL of LB broth only or LB broth +
100 mL of phage were also tested. The broth was incubated for 24 h
at 37 C with shaking at 100 rpm and lysis was followed by
measuring the OD600 of the solutions every 3 h.
2.4. In vivo assays
2.4.1. G. mellonella larva model
Larvae of G. mellonella were obtained from ‘La tourterelle des
bois’ (Comines-Warneton, Belgium) and stored at 4 C for a
maximum of 1 week. The larvae were inoculated into the
haemolymph behind the last right and/or left proleg by using a
30-gauge (G) insulin syringe (U-100) from BD Micro-FineTM
(Franklin Lakes, NJ, USA).
2.4.1.1. Preliminary experiments. Based on the in vitro assay results,
one mastitis-causing S. aureus isolate (Ani_OS001) was chosen for a
first preliminary experiment to assess infectivity. An aliquot of
10 mL of the bacterium was inoculated in three groups (A, B, C) of
ten larvae, each at different bacterial titres (A = 106 CFUs/10 mL,
B = 104 CFUs/10 mL, C = 102 CFUs/10 mL). Another group (D) of ten
larvae was inoculated with 10 mL of PBS and served as a negative
control. The mortality rate of the larvae was followed until 4 days
post-inoculation (DPI) to choose the optimal titre of isolate
Ani_OS001 that would kill at least 75% of the larvae at DPI 4. During
a second preliminary experiment, four other groups (E, F, G, H) of
ten larvae each were inoculated with isolate Ani_OS001 at the
optimal titre and with different concentrations of gentamicin
(Sigma-Aldrich, Germany) (E = 2.5 mg/10 mL, F = 5 mg/10 mL,
G = 7.5 mg/10 mL, H = 10 mg/10 mL) to choose the concentration
that would give 100% of larva survival at DPI 4.
2.4.1.2. Phage efficacy assessment. The first principal experiment
consisted of the inoculation of isolate Ani_OS001 at the optimalTable 3
Experimental design of the phage efficacy assessment in G. mellonella larvae performe
Groupsa S S_ROM S_REM S_ISP S_
Bacteria
(104 CFUs/10 mL)
    




a S, bacteria and PBS; S_ROM, bacteria and Romulus; S_REM, bacteria and Remus; S_IS
ISP; S_Gent, bacteria and Gentamycin; ROM, Romulus and PBS; REM, Remus and PBS; IStitre (104 CFUs/10 mL) with and without phages (Romulus, Remus
and/or ISP) at the multiplicity of infection (MOI) 1000, performed
in triplicate. The gentamicin (7.5 mg/10 mL) and the PBS were also
inoculated as positive and negative controls, respectively (Table 3).
Bacteria and treatments were inoculated 1 h apart. Mortality rate
was followed for 4 DPI and surviving larvae were sacrificed at DPI 4.
In parallel, independent groups of ten larvae (inoculated as
described) were blended at DPI 2 and DPI 4, respectively, to assess
the evolution of the bacterial and phage titres over time. A 10
phosphate-buffered saline (PBS) dilution of the blended suspen-
sion of each larvae group was spotted (10 mL) in triplicate on
Chapman agar (selective for staphylococci; VWR, Belgium) to
assess the bacterial titres. The same dilutions were spotted on LB
agar to estimate the phage titre after addition of 100 mL of
lysostaphin (to lyse the staphylococci; 0.1 mg/mL; Sigma–Aldrich,
Belgium), incubation at 37 C for 1 h, centrifugation at 46 000 rpm
for 45 min and filtration at 0.2 mm.
2.4.2. Murine mastitis model
The experimental protocol was approved by the Ethical
Committee of the University of Liège (approval number 14-1719)
and the experiments were conducted in a biosafety level 3
laboratory at the Faculty of Veterinary Medicine of the University
of Liège. Female BALB/cJRj specific-pathogen-free (SPF) mice
(Janvier, Saint Berthevin Cedex, France) of approximately 30 g
were used at 13 days of lactation. The pups were removed and
euthanised just before inoculation of the mammary glands. The
fourth abdominal mammary glands pair (left and right) were
inoculated using a 30-G insulin syringe (U-100 from BD Micro-
FineTM, Franklin Lakes, NJ, USA).
2.4.2.1. Preliminary experiment. The Ani_OS001 strain and the ISP
phage (chosen based on its in vitro lytic activity) were assessed,
respectively, for their infectivity and for their safety. Three groups
(A0 , B0, C0) of four mice each were inoculated (50 mL) with 105 CFUs
of Ani_OS001 (inoculum titre based on previous results, data not
shown), 108 PFU of ISP phage and PBS (negative control),d in triplicate.
MIX S_Gent ROM REM ISP Gent PBS
 
   
 
    2
P, bacteria and ISP; S_MIX, bacteria and the mix of the phages Romulus, Remus and
P, ISP and PBS; Gent, Gentamycin and PBS; PBS, PBS 2 times; , 10 mL of inoculum.
Fig. 1. Experimental design of the phage efficacy assessment in a murine mastitis model. HPI, hour post-inoculation; L4/R4, left/right fourth abdominal mammary gland pair;
Marbo, marbofloxacin.
Fig. 2. Activity of the phages on Ani_OS001 in LB broth. OD600, optical density at
600 nm; OS001, Ani_OS001 and LB broth; OS001_ROM, Ani_OS001, Romulus and LB
broth; OS001_REM, Ani_OS001, Remus and LB broth; OS001_ISP, Ani_OS001, ISP and
LB broth; OS001_MIX, Ani_OS001, the mix of the phages (Romulus, Remus and ISP)
and LB broth; ROM, Romulus and LB broth; REM, Remus and LB broth; ISP, ISP and LB
broth; MIX, mix of phages and LB broth; LB, LB broth only.
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all the mice were further inoculated with 50 mL of PBS. Two mice
were euthanised in each group after 24 h (HPI 24) and 48 h (HPI 48)
post-inoculation, respectively, their blood was collected and their
mammary glands were dissected for histopathological analysis
then blended with a Tissue lyser II (Qiagen, Hilden, Germany) for
bacterial counts. The S. aureus strain (Ani_OS001m) resulting from
the preliminary experiment was purified and used as an inoculum
for the phage efficacy assessment. The mouse presenting an
infection with the highest bacterial titre was selected to isolate the
strain (Ani_OS001m) to be used for the main experiment in order
to maximise the infection success.
2.4.2.2. Phage efficacy assessment. The strain Ani_OS001m was
used in one experiment after being checked phenotypically
(antimicrobial profile) and genetically (whole genome
sequencing) (Fig. 1). Five groups of four mice were used and 1 h
was left between two inoculations in the same mammary gland.
Marbofloxacin (antibiotic) and the PBS were used, respectively, as
positive and negative treatment controls. The mammary glands
were dissected and blended for bacterial and phage counting at HPI
24 and HPI 48 after dilutions in the PBS as described. The blood was
also collected for bacterial and phage titrations.
2.4.2.3. Mammary gland gross pathology and histopathology. The
mammary glands were observed for gross pathology using a score
from I (no inflammation) to V (severe inflammation) [17]. Then,
small samples were fixed in 4% buffered paraformaldehyde,
dehydrated with ethanol, cleared with xylene and embedded in
paraffin for histopathological studies. Tissue sections of 4-mm
thickness were stained with haematoxylin and eosin (H&E), and
examined by light microscopy at different magnifications. Each
sample was evaluated for the presence of necrosis, lymphocytic
inflammation, inflammatory cells (polymorphonuclear
neutrophils, granulocytes) and bacteria with a score from 0
(absent) to 4 (severe) [17].
2.5. Statistical analysis
Statistical analyses were performed on in vivo data with
GraphPad Prism8, (GraphPad Software, Inc., San Diego, CA, USA).
Kaplan–Meier survival curves and log-rank (Mantel–Cox) tests
were performed to analyse the G. mellonella larva survival curves.
Bonferroni's multiple comparisons test was used to compare the
variations of bacterial and phage titres inside G. mellonella larvae
and murine mammary glands.2.6. Whole genome sequencing comparison of Ani_OS001 and
Ani_0S001m
Staphylococcus aureus DNA was extracted from one colony of
Ani_OS001 and one colony of Ani_OS001m (recovered from the
mouse model preliminary experiment) using a protocol based on
lysostaphin followed by chloroform/isoamyl alcohol extraction.
Genomic libraries were prepared according to the manufacturer's
instructions using the Nextera XT DNA library preparation kit and
sequenced by the NovaSeq 6000 Sequencing System (Illumina, San
Diego, CA, USA). The raw reads sequences were assembled into
contigs with the pipeline shovill 1.0.4 including trimmomatic 0.38
for the cleaning and annotated using Prokka 1.13.3 [18]. The
comparison was performed by alignment of Ani_OS001m reads on
Ani_OS001 shovill assembly using bwa and VarScan variant calling
(-varFreq option set to 0.6 to ensure majority variants) [19].
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3.1. In vitro assay
CL and SCL were observed on LB agar for four MRSAs and five
MSSAs with the phages Romulus, Remus and/or ISP (Table 2).
Conversely, no lysis was observed with the phage DSM105264.
High EOP (>1) were observed for two MSSAs (Ani_OS001 and
Ani_GT110) and one MRSA (Ani_LG027). The Ani_OS001 isolate
that was lysed by the three phages was therefore chosen for the G.
mellonella experiments.
The same three phages, alone or together, had efficient lytic
activities on Ani_OS001 isolate in LB broth compared with positive
and negative controls (Fig. 2).
3.2. In vivo experiments
3.2.1. G. mellonella model
After inoculation of the larvae with the Ani_OS001 isolate, 100%
mortality was observed in group A, 80% in group B and 40% in
group C at DPI 4 during the first preliminary experiment
(determination of the infectious dose). In the second preliminary
experiment (determination of the therapeutic dose of gentamicin)
30% of survival was observed in group E, 70% in group F and 100% in
groups G and H at DPI 4. Based on these results, 104 CFUs/10 mL
(group B) and 7.5 mg/10 mL (group G) were chosen as the optimal
bacterial infectious dose and optimal gentamicin therapeutic dose,
respectively, for subsequent experiments.
During the principal experiment, a 10% survival rate was
observed in the larvae inoculated with Ani_OS001 isolate and PBS,
whereas 90% of the larvae inoculated with Ani_OS001 isolate and
gentamicin survived at DPI 4. Survival rates at DPI 4 ranged from
20% to 35% in the groups inoculated with Ani_OS001 isolate and
the phages (Romulus, Remus, ISP or the mix of the three phages)
(Fig. 3).
High S. aureus titres (5 1011 CFUs/mg and 2  1012 CFUs/mg)
were obtained at DPI 2 and DPI 4, respectively, from the blended
larvae inoculated with Ani_OS001 isolate and PBS. These titres
were lower than the larvae inoculated with Ani_OS001 and phage
(s) (Fig. 4A). The phage titres increased between DPI 2 and DPI 4 in
the larvae inoculated with Ani_OS001 isolate and stayed very
stable in the groups inoculated only with the phage(s) (Fig. 4B).
3.2.2. Murine mastitis model
3.2.2.1. Preliminary experiment. Mammary gland inflammations
were observed in group A0 with a bacterial titre up to 4.2 104
CFUs/mg at HPI 48, whereas neither inflammation nor infectionFig. 3. Kaplan–Meier survival curves of G. mellonella larvae. OS001_PBS, Ani_OS001
and PBS; OS001_ROM, Ani_OS001 and Romulus; OS001_REM, Ani_OS001 and
Remus; OS001_ISP, Ani_OS001 and ISP; OS001_MIX, Ani_OS001 and the mix of
Romulus, Remus and ISP, OS001_Genta, Ani_OS001 and gentamicin; DPI, days post-
inoculation.
Fig. 4. (A) Bacterial titres in blended G. mellonella larvae.a (B) Phage titres in
blended G. mellonella larvaea. aOS001_PBS, Ani_OS001 and PBS; OS001_ROM,
Ani_OS001 and Romulus; OS001_REM, Ani_OS001 and Remus; OS001_ISP,
Ani_OS001 and ISP; OS001_MIX, Ani_OS001 and the mix of the phages Romulus,
Remus and ISP; ROM, Romulus and PBS; REM, Remus and PBS; ISP, ISP and PBS; PBS,
PBS 2 times; DPI, days post-inoculation; I, inoculum titre; statistically significant
difference between values (*P < 0.05; **P < 0.01 (determined by Bonferroni multiple
comparison test)].
Table 4
Results of the preliminary experiment (mice model).a







HPI24 2.80E+04 0.00E+00 0.00E+00
HPI48 4.20E+04 0.00E+00 0.00E+00
a HPI, hour post-inoculation.
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was detected in the mouse blood.
3.2.2.2. Main experiment. At necropsy, gross pathology scores
were established for the 40 mammary glands of the 20 mice
(Fig. 5). Score values of III and V with redness and slimy exudate of
the gland were observed in the mammary glands inoculated with
Ani_OS001m isolate and PBS, whereas the mammary glands
inoculated with Ani_OS001m isolate and the ISP phage had score
values of II and III with slightly red glands. The other three groups
of mice had score values between I and II with very little redness of
the glands.
Histopathology was performed on the 40 mammary glands and
an average score was established for each group (Fig. 6). The groupFig. 5. Gross pathology of the mammary glands. OS001_ISP, Ani_OS001m and the ISP ph
PBS; ISP_PBS, ISP phage and PBS; PBS_PBS, PBS twice, HPI, hour post-inoculation. Clinic
highly moderate inflammation; V, severe inflammation.
Fig. 6. Mammary gland histopathology. OS001_ISP, Ani_OS001m and ISP phage; OS001_M
ISP phage and PBS; PBS_PBS, PBS twice, A, tissue necrosis (degeneration); B, polymorpho
absent, 1. minimal, 2, mild, 3, moderate, 4, severe. 10, ten-fold magnification; 100, 1inoculated with Ani_OS001m isolate and PBS had severe tissue
necrosis and high numbers of polymorphonulear neutrophils
(PMN), lymphocytes and bacteria. In the group inoculated with
Ani_OS001m isolate and ISP phage, the lesions were moderate and
in the three others groups, they were very weak with no bacteria
and no tissue necrosis. Moderate amounts of macrophages were
also present in all mice.
A high bacterial titre was observed in the blended mammary
glands of the group inoculated with Ani_OS001m isolate and PBS at
HPI 24 and HPI 48, whereas a progressive decrease of the bacterial
titres was observed between HPI 24 and HPI 48 in the group
inoculated with Ani_OS001m isolate and ISP phage. A drastic
decrease was observed in the group inoculated with Ani_OS001m
isolate and treated with marbofloxacin at HPI24 leading to the
absence of bacterial detection at HPI 48. No bacterial growth was
observed in the other two groups (Fig. 7A, Table 5). No bacteria or
phages were detected in the mouse blood.
A progressive decrease of the phage titres was observed
between HPI 24 and HPI 48 in the two groups inoculated with
phage. The decrease of the phage titre was more rapid and drastic
in the group inoculated with Ani_OS001m isolate and ISP phage
leading to the absence of phage detection at HPI48 than in the
group inoculated with ISP phage and PBS (Fig. 7B, Table 5). No
phage was detected in the other three groups.age; OS001_Marbo, Ani_OS001m and marbofloxacin; OS001_PBS, Ani_OS001m and
al score: I, no inflammation; II, mild inflammation; III, moderate inflammation; IV,
arbo, Ani_OS001m and marbofloxacin; OS001_PBS, Ani_OS001m and PBS; ISP_PBS,
nulear neutrophils (PMNs) and lymphocytes; C, macrophages; D, bacteria; Score: 0,
00-fold magnification.
Fig. 7. (A) Mean of the bacterial titres in the mammary gland.a (B) Mean of the phage titres in the mammary glanda. aOS001_ISP, Ani_OS001m and the ISP phage;
OS001_Marbo, Ani_OS001m and marbofloxacin; OS001_PBS, Ani_OS001m and PBS; ISP_PBS, ISP phage and PBS; PBS, PBS twice. Each bar on the graphs represents the mean of
the bacterial or phage titres in four mammary glands (two mice per group). I, Inoculum; statistically significant difference between values [*P < 0.05 (determined by
Bonferroni multiple comparison test)]. Error bars represent standard error.
Table 5
Results of the phage efficacy assessment in murine mastitis model.a
Groups OS001_ISP OS001_Marbo OS001_PBS ISP_PBS PBS_PBS
HPI n HPI 24 HPI 48 HPI 24 HPI 48 HPI 24 HPI4 8 HPI 24 HPI 48 HPI 24 HPI 48
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a OS001_ISP, Ani_OS001m and the ISP phage; OS001_Marbo, Ani_OS001m and marbofloxacin; OS001_PBS, Ani_OS001m and PBS; ISP_PBS, ISP phage and PBS; PBS_PBS, PBS
twice; M, mouse; L4/R4 = Left and right fourth abdominal mammary gland pair; –, no bacterial or phage titre; HPI, hour post-inoculation.
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A significant difference was observed between the
survival curves of the infected-gentamicin-treated,  on the one
hand, and the infected-phage-treated and infected-PBS-treated
G. mellonella larvae groups, on the other hand, as determined
by log-rank (Mantel Cox) test (P < 0.0001). A significant difference
was also detected between the bacterial titres of the infected-PBS-
treated and the infected-phage-treated larva groups as deter-
mined by the Bonferroni multiple comparison test (P < 0.05).
This test also showed a higher significant difference between
the bacterial titres of the infected-PBS-treated and the non-
infected larva groups (P < 0.01). In the murine mastitis model,
the Bonferroni multiple comparison test showed a
significant difference between the bacterial titres of the
infected-PBS-treated and the infected-phage-treated mammary
glands (P < 0.05). In both G. mellonella and mouse models, asignificant difference (P < 0.05) was observed between the phage
titres of the infected-phage-treated and the ‘non-infected’-phage-
treated groups.
3.2.4. Genome comparison of Ani_OS001 and Ani_OS001m
The draft genome of Ani_OS001 and Ani_OS001m are available
from GenBank, accession numbers VXKU01000000 and
VXKV01000000, respectively. The VarScan analysis revealed only
two single polymorphism nucleotide (SNPs) between the two
strains. One is associated with a region without any annotation
according to Prokka (position 25 of contig OS001-00027 C → T).
The second SNP (G → T) occurred in position 60 157 of contig
OS001-00001. The Prokka annotation revealed SdrE, a gene coding
for a member of the microbial surface components recognizing
adhesive matrix family molecule (MSCRAMM). This mutation
resulted in a G899V mutation at the protein level.
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This study highlights the therapeutic potential of bacterio-
phages against S. aureus associated with bovine mastitis by the in
vitro assessment of the phage activities and the in vivo assessment
of the phage efficacy in G. mellonella and murine mastitis models.
Different lytic activities were observed on ten S. aureus isolates:
the phage Romulus was active against only one isolate, the phage
Remus against four isolates and the phage ISP against nine isolates.
In previous studies, the Romulus and Remus phages were active
against more isolates tested (70%) [11], whereas the lytic activity of
the ISP phage was observed against a similar percentage (87%) of
the tested S. aureus isolates, including MRSA [12,20]. Conversely,
none of the ten isolates tested was susceptible to the DSM105264
phage, although it was demonstrated to be active against ca. half of
the previously tested isolates (human strains) [13]. The difference
of susceptibility observed could be explained by the difference of
the S. aureus origins (bovine vs. human).
The lytic activities of the three different phages against the
Ani_OS001 S. aureus strain in broth medium confirm the results
observed on agar medium. However, a higher efficiency has been
observed for the phages ISP and REM compared with those of the
phage mix, itself more efficient than the phage ROM alone. As
showed in the literature, the mix of phages usually leads to
synergistic effect in vitro in terms of a broad host range [21,22].
This study showed a probable lower effect of the phages mix
compared with those of individual phages when using them
against the same bacteria.
In the G. mellonella model, using only the Ani_OS001 strain, no
significant difference was observed between the survival rate of
the infected-phage-treated and infected-PBS-treated larvae group,
whereas this difference was significant in comparison to the
infected-gentamicin-treated group. The higher bacterial titre
observed at DPI 4 in the blended larvae (group OS001_ISP) with
the ISP phage compared with those observed with Romulus and
Remus, although its higher lytic activity in vitro can be explained
by its initial adsorption and biofilm-degradation that are slower
than those of Romulus and Remus phages [11]. Another explana-
tion could be the occurrence of a mutation in the bacterial genome
during the phage treatment making a part of the Ani_OS001 isolate
population resistant to the ISP phage [23,24]. No SPF larvae exist,
and natural carriage of S. aureus could affect the results of the
blended larvae bacterial titres. The very weak impact of natural
carriage on our results has been confirmed by the Bonferroni
multiple comparison test showing a higher significant difference
(P < 0.01) between the bacterial titres of larva groups with natural
carriage (REM, ISP, PBS) compared with those of the infected-PBS-
treated larva groups. Moreover, a decrease in phage titre was
observed for the blended larvae at DPI 2 and DPI 4. This could be
explained by the single dose of phages inoculated and their
possible inactivation as demonstrated in recent studies where
bacteriophages have been shown to be efficient in G. mellonella
larvae after multiple inoculations in the presence of the bacteria
and depending on the MOI [25,26]. The decrease of the phage titre
observed in this study is slower in the infected-phage-treated
groups compared with the ‘non-infected’-phage-treated groups
meaning that a simultaneous replication of the phage and bacteria
occurred inside the larvae. This study reports for the first time
results on lytic bacteriophages assessment on S. aureus in the G.
mellonella model, whereas many other studies were already
performed, but on other pathogen bacteria [10,25,27]. However,
the results observed in this model need to be confirmed in other
infectious models in mammals, such as in the murine mastitis
model.
An increase of the virulence gene expression after a previous in
vivo passage is often observed as reviewed by Angelichio andCamilli [28]. In the murine mastitis model, Ani_OS001m showed a
more efficient infection than Ani_OS001. The WGS of both strains
revealed a mutation in the SdrE gene of Ani_OS001m. SdrE is
presented as a key factor for S. aureus being invasive and has
already been described in an S. aureus strain showing higher
virulence in mastitis cases [29].
A reduction of the inflammation in mice mammary glands
was obtained in the infected-phage-treated group compared
with those observed in the infected-PBS-treated group with the
strain Ani_OS001m. These observations have also been described
in recent studies on the therapeutic assessment of phage against
S. aureus in a murine mastitis model [17,30]. An increase of the
bacterial titre (from 7  104 to 2  108 CFUs/mg) observed in the
infected-PBS-treated group and a decrease of the bacterial titre
(from 7  104 to 5 103 CFUs/mg) observed in the infected-phage-
treated group highlight the efficacy of the phage against the S.
aureus strain in the mice mammary glands, as already shown with
other phages in previous studies [30,31]. Nevertheless, this phage
efficacy was less important than the one obtained with
antimicrobials in the murine model [17]. Moreover, a decrease
of the phage titre was observed in the ‘non-infected’-phage-
treated group (from 1.3  108 to 9  102 PFUs/mg) and more
drastically in the infected-phage-treated group (from 1.3  108 to
0 PFUs/mg), suggesting an elimination or a degradation of the
phage in the mouse mammary gland. Studies show that the
stimulation of the immune response (macrophages, serum
complement system) is more important when bacteria are
inoculated with phages in the mice mammary glands, which
can explain the drastic decrease of the phage titre in the infected-
phage-treated groups [17,23,32]. The intra-mammary route can
be favourable to the phage inactivation by some proteins and
lipids presents in the milk leading to a decrease of the phage titre
in the mammary gland [23,33]. Conversely, no decrease of the
phage titre was observed in the mice mammary glands showing
moderate inflammation as described by Breyne et al. [17], who
assessed a phage cocktail effect on S. aureus at MOI 105. This
contradiction with our study could be explained by the use of a
single phage inoculation at a lower MOI (103), which would have
been quickly eliminated.
This study highlights the lytic activity of three bacteriophages
(Romulus, Remus and ISP) against S. aureus associated with bovine
mastitis in vitro and their efficacy in vivo materialised by a larvae
survival rate below 50% at DPI 4 in the groups infected and treated
(with the three phages) and an incomplete recovery of the mouse
mastitis at HPI 48 in the groups infected and treated (with the ISP
phage). Moreover, significant differences were observed between
infected-PBS-treated and infected-phage-treated groups in G.
mellonella and murine mastitis model demonstrating an effect
of the three phages against S. aureus associated with bovine
mastitis. The weak efficacy of phage observed in vivo (low larvae
survival rate, incomplete mammary gland recovery) could be
related to the unique bacteriophage dose used, the ratio phage/
bacteria (MOI), the role of the immune system and the route of
inoculation as described in previous studies [32,34]. Further
studies are required to assess these parameters in order to confirm
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